Safety and tolerability of eprosartan

Pharmacotherapy

Volumn 19, Issue 4 II, 1999, Pages

  Gavras, Irene ^a   Gavras, Haralambos ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN;

ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DOSE CALCULATION; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 0032898226     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.7.102s.30945     Document Type: Review

References (28)

1. National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Washington, DC: National Institutes of Health, 1997.
2. Hosie J, Wilkund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995;9(suppl):S15-19.
3. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens 1996;18:463-72.
4. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54:885-902.
5. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311.
6. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998;55:713-18.
7. Gavras H, Salerno CM. The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996;18:1058-67.
8. Csajka C, Buclin T, Brunner HR, et al. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997;32:1-29.
9. Francis CK. Hypertension, cardiac disease, and compliance in minority patients. Am J Med 1991;91(suppl 1A):S29-36.
10. SmithKline Beecham Pharmaceuticals. Summary of product characteristics. King of Prussia, PA;1998.
11. Goldberg A, Sweet C. Efficacy and safety of losartan. Can J Cardiol 1995;11(suppl F):27F-32.
12. SmithKline Beecham Pharmaceuticals. Data on file. King of Prussia, PA.
13. Weber M. Efficacy and safety of eprosartan in patients with essential hypertension: results of an 8-week, double-blind, placebo controlled, multicenter trial. J Hypertens 1998;16(suppl 2):S245.
14. Hedner T, Himmelmann A, for the Eprosartan Multinational Study Group. The efficacy and tolerance of one and two daily doses of eprosartan in essential hypertension. J Hypertens 1999;17(1):129-36.
15. Wilking S, Van B, Belanger A, et al. Determinants of isolated systolic hypertension. JAMA 1988;260:3451-5.
16. Harland D, Duff D, Laing S, et al. Safety of eprosartan in elderly patients with hypertension [abstr]. Am J Hypertens 1998;11:78A.
17. Elliot W. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J Hum Hypertens In press.
18. Argenziano L, Trimarco B. Effect of eprosartan and enalapril in treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999;15(1):9-14.
19. Levine B. Effect of eprosartan and enalapril in treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999;15(1):25-32.
20. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992;117:234-42.
21. Oparil S. Eprosartan versus enalapril in hypertensive patients with angiotensin-converting enzyme inhibitor-induced cough. Curr Ther Res 1999;60(1):1-14.
22. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999;15(1):15-24.
23. Illson B. Drug interaction studies with eprosartan, a novel angiotensin II receptor antagonist [abstr]. Am J Hypertens 1998;11:108A.
24. Martin DE, Tompson D, Boike SC, et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br J Clin Pharmacol 1997;43:661-4.
25. Martin DE, DeCherney GS, Ilson B, et al. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. J Clin Pharmacol 1997;37:155-9.
26. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997;62:417-25.
27. Blum RA, Kazierad D, Tenero DM. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy 1999:19(4 pt 2):79S-85.
28. Weber M. Clinical efficacy of eprosartan. Pharmacotherapy 1999;19(4 pt 2):95S-101.